Recent discussions on X about Iterum Therapeutics (ITRM) have centered around the company's awaiting FDA decision on a key drug application, which has sparked significant interest among investors. The stock recently saw a sharp intraday surge, with some noting a price increase of over 18%, marking its highest level in months. Many are speculating on the potential impact of a favorable ruling, with conversations buzzing about the implications for the company's future in antibiotic resistance treatments.
The dialogue on X also reflects anticipation for upcoming financial updates, as the company is set to release its quarterly results soon, adding another layer of intrigue. Some participants in the discussions are optimistic, pointing to analyst ratings and the potential for strong market positioning if clinical milestones are achieved. This heightened activity on social platforms underscores the critical juncture at which Iterum Therapeutics currently stands.
Note: This discussion summary was generated from an AI condensation of post data.
Iterum Therapeutics Insider Trading Activity
Iterum Therapeutics insiders have traded $ITRM stock on the open market 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $ITRM stock by insiders over the last 6 months:
- MICHAEL W. DUNNE purchased 15,000 shares for an estimated $10,854
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
Iterum Therapeutics Hedge Fund Activity
We have seen 3 institutional investors add shares of Iterum Therapeutics stock to their portfolio, and 9 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- RENAISSANCE TECHNOLOGIES LLC removed 197,916 shares (-45.1%) from their portfolio in Q1 2025, for an estimated $243,436
- ONEDIGITAL INVESTMENT ADVISORS LLC added 60,000 shares (+59.4%) to their portfolio in Q2 2025, for an estimated $59,700
- CITADEL ADVISORS LLC removed 21,207 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $26,084
- LEE FINANCIAL CO removed 16,000 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $15,920
- TWO SIGMA SECURITIES, LLC added 10,709 shares (+inf%) to their portfolio in Q1 2025, for an estimated $13,172
- JANE STREET GROUP, LLC removed 10,262 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $12,622
- UBS GROUP AG added 5,625 shares (+183.0%) to their portfolio in Q1 2025, for an estimated $6,918
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Iterum Therapeutics Analyst Ratings
Wall Street analysts have issued reports on $ITRM in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 05/08/2025
To track analyst ratings and price targets for Iterum Therapeutics, check out Quiver Quantitative's $ITRM forecast page.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
